서울대학교 중앙도서관
S-Space 소개
My S-Space
로그인이 필요합니다.
Login

S-Space

Browse

Author

Jump to a point in the index
Or type in a year

  • Sort by
  • In order
  • Results/Page
  • Authors/record

Showing results 61 to 118 of 118

Issue DateTitle / Author(s) / CitationFileAltmetrics
2017-04
AZD6738, A Novel Oral Inhibitor of ATR, Induces Synthetic Lethality with ATM Deficiency in Gastric Cancer Cells
DOI
2017-05
Late chronotypes are associated with neoadjuvant chemotherapy-induced nausea and vomiting in women with breast cancer
DOI
2017-06
Prospective Evaluation of Changes in Tumor Size and Tumor Metabolism in Patients with Advanced Gastric Cancer Undergoing Chemotherapy: Association and Clinical Implication
DOI
2017-07
Antitumor Effect of KX-01 through Inhibiting Src Family Kinases and Mitosis
DOI
2017-10
Korean Cancer Patients' Awareness of Clinical Trials, Perceptions on the Benefit and Willingness to Participate
view fileDOI
2017-10
Bilateral Salpingo-oophorectomy Compared to Gonadotropin-Releasing Hormone Agonists in Premenopausal Hormone Receptor-Positive Metastatic Breast Cancer Patients Treated with Aromatase Inhibitors
DOI
2017-10
Skeletal muscle depletion predicts survival of patients with advanced biliary tract cancer undergoing palliative chemotherapy
DOI
2017-11
Phase II, multicentre, randomised trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy in patients with HER2-negative metastatic breast cancer
DOI
2017-12
Cyclophosphamide, Methotrexate, and 5-Fluorouracil as Palliative Treatment for Heavily Pretreated Patients with Metastatic Breast Cancer: A Multicenter Retrospective Analysis
DOI
2017-12
Treatment Patterns and Outcomes in Elderly Patients with Metastatic Breast Cancer: A Multicenter Retrospective Study
DOI
2018-01
S-1-induced lacrimal drainage obstruction and its association with ingredients/metabolites of S-1 in tears and plasma: A prospective multi-institutional study
DOI
2018-03
Integrated 18F-FDG PET/MRI in breast cancer: Early prediction of response to neoadjuvant chemotherapy

Cho, Nariya; Im, Seock-Ah; Cheon, Gi Jeong; Park, In-Ae; Lee, Kyung-Hun; Kim, Tae-Yong; Kim, Young Seon; Kwon, Bo Ra; Lee, Jung Min; Suh, Hoon Young; Suh, Koung Jin

European Journal of Nuclear Medicine and Molecular Imaging, Vol.45 No.3, pp.328-339

DOI
2018-03
A phase II trial of S-1 and oxaliplatin in patients with advanced hepatocellular carcinoma
DOI
2018-05
Cyclin E overexpression confers resistance to the CDK4/6 specific inhibitor palbociclib in gastric cancer cells
DOI
2018-05
Pre-treatment anxiety is associated with persistent chemotherapy-induced peripheral neuropathy in women treated with neoadjuvant chemotherapy for breast cancer
DOI
2018-11
Fulvestrant plus goserelin versus anastrozole plus goserelin versus goserelin alone for hormone receptor-positive, HER2-negative tamoxifen-pretreated premenopausal women with recurrent or metastatic breast cancer (KCSG BR10-04): a multicentre, open-label, three-arm, randomised phase II trial (FLAG study)
DOI
2018-12
A phase II trial of the pan-HER inhibitor poziotinib, in patients with HER2-positive metastatic breast cancer who had received at least two prior HER2-directed regimens: results of the NOV120101-203 trial
DOI
2018-12
Effects of trastuzumab on locoregional recurrence in human epidermal growth factor receptor 2-overexpressing breast cancer patients treated with chemotherapy and radiotherapy

Jeon, Seung Hyuck; Shin, Kyung Hwan; Kim, Jin Ho; Kim, Kyubo; Kim, In Ah; Lee, Kyung-Hun; Kim, Tae-Yong; Im, Seock-Ah

Breast Cancer Research and Treatment, Vol.172 No.3, pp.619-626

DOI
2019-01
Randomized Open Labe Phase III Trial of Irinotecan Plus Capecitabine versus Capecitabine Monotherapy in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane: PROCEED Trial (KCSG BR 11-01)
DOI
2019-05
Quality of life outcomes including neuropathy-associated scale from a phase II, multicenter, randomized trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy for HER2-negative metastatic breast cancer: Korean Cancer Study Group Trial (KCSG BR13-11)
view fileDOI
2019-05
Prognostic effects of abnormal DNA damage response protein expression in breast cancer
DOI
2019-07
Prognostic role of body mass index is different according to menopausal status and tumor subtype in breast cancer patients
DOI
2019-07
Immune recurrence score using 7 immunoregulatory protein expressions can predict recurrence in stage I–III breast cancer patients
DOI
2019-11
A phase I/II study of poziotinib combined with paclitaxel and trastuzumab in patients with HER2-positive advanced gastric cancer
DOI
2019-11
Exploratory biomarker analysis from a phase II clinical trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine for HER2-negative metastatic breast cancer patients (KCSG BR13-11)
DOI
2019-12
Prognostic Impact of Pregnancy in Korean Patients with Breast Cancer
DOI
2019-12
Amenorrhea and menopause in patients with breast cancer after chemotherapy
DOI
2019-12
Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): A multicentre, open-label, randomised, phase 2 trial
DOI
2020-02
TDP1 and TOP1 Modulation in Olaparib-Resistant Cancer Determines the Efficacy of Subsequent Chemotherapy
view fileDOI
2020-03
Morning chronotype is a protective factor against chemotherapy-induced hot flashes in premenopausal women with breast cancer
DOI
2020-03
The effect of perceived social support on chemotherapy-related symptoms in patients with breast cancer: A prospective observational study
DOI
2020-04
Prognostic role of androgen receptor expression in surgically resected early breast cancer patients
DOI
2020-04
Development of a Nomogram to Predict the Recurrence Score of 21-Gene Prediction Assay in Hormone Receptor–Positive Early Breast Cancer
DOI
2020-06
Effect of timing of gonadotropin-releasing hormone agonist administration for ovarian protection in patients with breast cancer
DOI
2020-07
Prediction of pathologic complete response using image-guided biopsy after neoadjuvant chemotherapy in breast cancer patients selected based on MRI findings: a prospective feasibility trial
DOI
2020-07
Immunogenicity of influenza vaccination in patients with cancer receiving immune checkpoint inhibitors
DOI
2020-10
Circulating Osteocalcin-Positive Cells as a Novel Diagnostic Biomarker for Bone Metastasis in Breast Cancer Patients
DOI
2020-10
Adjuvant Chemotherapy in Microsatellite Instability-High Gastric Cancer
DOI
2021-01
Genomic profile of metastatic breast cancer patient-derived xenografts established using percutaneous biopsy
DOI
2021-01
Association of insulin, metformin, and statin with mortality in breast cancer patients
DOI
2021-02
Phase II Study of Avelumab in Patients with Advanced Hepatocellular Carcinoma Previously Treated with Sorafenib
DOI
2021-02
Intensity of metastasis screening and survival outcomes in patients with breast cancer
DOI
2021-08
Predictive biomarkers for 5-fluorouracil and oxaliplatin-based chemotherapy in gastric cancers via profiling of patient-derived xenografts
DOI
2022
Do posttraumatic stress symptoms predict trajectories of sleep disturbance and fatigue in patients with breast cancer? A parallel-process latent growth model
DOI
2022-02
Morning Chronotype Decreases the Risk of Chemotherapy-Induced Peripheral Neuropathy in Women With Breast Cancer
DOI
2022-03
Psychiatric symptoms mediate the effect of resilience on health-related quality of life in patients with breast cancer: Longitudinal examination
DOI
2022-04
A Real-World Efficacy of Nab-Paclitaxel Monotherapy in Metastatic Breast Cancer
DOI
2022-06
Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, single-centre, phase 2 study
DOI
2022-06
The longitudinal effects of chronotype on chemotherapy-induced nausea and vomiting in patients with breast cancer receiving neoadjuvant chemotherapy
DOI
2022-08
Do posttraumatic stress symptoms predict trajectories of sleep disturbance and fatigue in patients with breast cancer? A parallel-process latent growth model
DOI
2022-10
Musculoskeletal Pain and the Prevalence of Rheumatoid Arthritis in Breast Cancer Patients During Cancer Treatment: A Retrospective Study

Kim, Ju Yeon; Kim, Min Jung; Lee, Eun Bong; Kim, Tae-Yong; Lee, Kyung-Hun; Im, Seock-Ah; Park, Jin Kyun

Journal of Breast Cancer, Vol.25 No.5, pp.404-414

DOI
2022-11
Prognostic role of tumor subtype and germline BRCA mutation in advanced breast cancer patients treated with palbociclib plus endocrine therapy
DOI
2022-11
The Effect of Temperament on the Association Between Pre-treatment Anxiety and Chemotherapy-Related Symptoms in Patients With Breast Cancer
DOI
2023-01
Mutations of TP53 and genes related to homologous recombination repair in breast cancer with germline BRCA1/2 mutations
DOI
2023-05
Genetic and immune microenvironment characterization of HER2-positive gastric cancer: Their association with response to trastuzumab-based treatment
DOI
2023-12
HER2 amplification level by in situ hybridization predicts survival outcome in advanced HER2-positive breast cancer treated with pertuzumab, trastuzumab, and docetaxel regardless of HER2 IHC results
DOI
2023-12
HER2 amplification level by in situ hybridization predicts survival outcome in advanced HER2-positive breast cancer treated with pertuzumab, trastuzumab, and docetaxel regardless of HER2 IHC results
view fileDOI
2024-01
Pemetrexed plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer (KCSG-BR15-17): A randomized, open-label, multicenter, phase II trial
DOI
1 2